Review of ctDNA in breast cancer - present utility and future perspectives
Circulating tumor DNA testing increasingly enables treatment response monitoring in hormone-responsive breast cancer, moving closer to routine clinical adoption.
This narrative review in a Polish oncology journal surveys ctDNA applications across the breast cancer disease continuum, covering early detection, minimal residual disease monitoring, treatment response, and resistance mechanism identification. The review provides a practical clinician-oriented summary without new data, noting ctDNA is approaching adoption particularly for MRD monitoring in HR+/HER2- breast cancer.
What the study was
- Study design
- narrative_review
- Category
- early_cancer_detection_liquid_biopsy
- Maturity
- Exploratory
- Journal
- Reports of Practical Oncology and Radiotherapy
Why it surfaced
Standard ctDNA-breast cancer review with modest novelty; useful for pipeline awareness but does not advance the field. Score 4 (N=1, D=1, P=1, E=1) for narrative review without original data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.